Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. demonstrated significant financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, a remarkable increase of 105% quarter-over-quarter, alongside improved gross margins of 60.3%. The sequential growth in revenues indicates a potential rebound from previous challenges, suggesting that earlier delays may have been unique to that period. Additionally, the company's strategic move to enter a non-binding merger agreement with Applied Digital Cloud highlights its commitment to growth and innovation in the exoskeleton market.

Bears say

Ekso Bionics Holdings Inc experienced a revenue miss in the prior quarter, attributed to two significant order delays totaling $1.5 million, which raises concerns about the reliability of its enterprise sales segment. The company's reported revenues for 3Q25 were $4.23 million, slightly above consensus estimates, but the net loss per share of $0.54 indicates ongoing financial challenges. Furthermore, the removal of the previous price target and downgrade to Neutral reflects a general lack of confidence in the company's ability to achieve consistent growth and profitability in the near term.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.